Cite
HARVARD Citation
Pivot, X. et al. (2017). Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. European journal of cancer. pp. 151-160. [Online].